Kura Oncology (NASDAQ:KURA) Posts Quarterly Earnings Results, Beats Expectations By $0.04 EPS

Key Points

• Kura Oncology reported a quarterly loss of $0.78 per share, beating analyst expectations by $0.04, while revenue of $22.84 million fell short of the $24.94 million consensus estimate.
• Analysts have a consensus “Moderate Buy” rating and an average price target of $25.35; recommendations include 11 Buys, one Hold, and one Sell.
• Shares were unchanged at $7.57 on Tuesday. Company insiders sold 153,881 shares worth about $1.71 million over the past three months.

Kura Oncology (NASDAQ:KURA - Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($0.78) EPS for the quarter, topping analysts' consensus estimates of ($0.82) by $0.04, FiscalAI reports. Kura Oncology had a negative return on equity of 207.18% and a negative net margin of 384.30%. The company had revenue of $22.84 million during the quarter, compared to the consensus estimate of $24.94 million.

Kura Oncology Stock Performance

Shares of KURA stock remained flat at $7.57 during trading hours on Tuesday. The stock had a trading volume of 2,428,787 shares, compared to its average volume of 1,719,776. Kura Oncology has a 52 week low of $6.75 and a 52 week high of $13.90. The company has a debt-to-equity ratio of 0.12, a current ratio of 4.73 and a quick ratio of 4.71. The stock's 50 day moving average is $10.60 and its two-hundred day moving average is $9.79. The company has a market cap of $673.43 million, a price-to-earnings ratio of -2.25 and a beta of 0.56.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. JPMorgan Chase & Co. began coverage on Kura Oncology in a research report on Thursday, October 1st. They set an "overweight" rating and a $30.00 price objective on the stock. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Kura Oncology in a research report on Thursday, October 15th. Deutsche Bank Aktiengesellschaft set a $24.00 price target on shares of Kura Oncology in a research note on Wednesday, October 14th. Barclays set a $24.00 price target on shares of Kura Oncology in a report on Wednesday, October 14th. Finally, Morgan Stanley set a $24.00 price objective on shares of Kura Oncology in a research note on Monday, August 24th. Eleven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Kura Oncology has an average rating of "Moderate Buy" and a consensus target price of $25.35.

Insider Buying and Selling at Kura Oncology

In related news, insider Francis Burrows sold 20,726 shares of the business's stock in a transaction on Thursday, September 24th. The stock was sold at an average price of $10.83, for a total value of $224,462.58. Following the sale, the insider owned 42,327 shares of the company's stock, valued at $458,401.41. The trade was a 32.87% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Teresa Bair sold 31,487 shares of the company's stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $12.63, for a total value of $397,680.81. Following the completion of the sale, the insider owned 195,444 shares in the company, valued at $2,468,457.72. This trade represents a 13.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 153,881 shares of company stock worth $1,708,183 over the last three months. 7.60% of the stock is currently owned by insiders.

About Kura Oncology

Kura Oncology is a biopharmaceutical company focused on developing precision medicines for cancer. Its research has centered on therapies that target molecular pathways involved in tumor growth and blood cancers. The company's best-known program is ziftomenib, an oral menin inhibitor developed for acute myeloid leukemia, including forms associated with NPM1 mutations or KMT2A rearrangements. Kura has also worked on other targeted cancer therapies. Based in San Diego, California, Kura conducts drug development and clinical research in the United States and has worked with international partners to advance its programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.